Company intelligence / Profile preview

Bone Health Technologies

Redwood City, California, United Statesosteoboost.com ↗

Ownership: Private
Development stage: Commercial

Overview

Osteoboost demonstrated significant reduction in the decline of bone strength and density for postmenopausal women with osteopenia in a pivotal randomized, sham-controlled clinical trial. Earlier pilot studies showed reduced bone breakdown activity after short-term use. The product received FDA clearance through the de novo pathway in early/mid 2024.

Therapeutic areas: EndocrinologyWomen's Health
Modalities: Device (specifically wearable vibration therapy device)Non-pharmacological therapyDigital health platform (with acquisition of Wellen)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Osteoboost

Commercial

Indications: Osteopenia, Osteoporosis

Beyond the preview

Go deeper on Bone Health Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bone Health Technologies.

Explore the full profile